# PDUFA dates May 2028: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2028-05

> 28 FDA catalysts are dated in May 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## All catalysts in May 2028

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 2028 | [Dupilumab coformulated with berahyaluronidase alfa primary completion](https://sec-api.dev/pdufa/dupilumab-coformulated-with-berahyaluronidase-alfa) | SNY | Dermatitis Atopic | scheduled | "NCT07919899 (Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-05-02 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07919899)) |
| May 2028 | [PF-08653944 primary completion](https://sec-api.dev/pdufa/pf-08653944) | PFE | Obesity; Overweight and/or Obesity; Overweight | scheduled | "NCT07595549 (A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07595549)) |
| May 2028 | [Cosentyx (secukinumab) primary completion](https://sec-api.dev/pdufa/secukinumab) | NVS | Polymyalgia Rheumatica | scheduled | "NCT06331312 (Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-08 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06331312)) |
| May 2028 | [Low dose pf-07328948 primary completion](https://sec-api.dev/pdufa/low-dose-pf-07328948) | PFE | Heart Failure | scheduled | "NCT06991257 (A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-05-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06991257)) |
| May 2028 | [Duvakitug primary completion](https://sec-api.dev/pdufa/duvakitug) | SNY | Ulcerative Colitis | scheduled | "NCT07184996 (An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-09 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07184996)) |
| May 2028 | [Opevesostat primary completion](https://sec-api.dev/pdufa/opevesostat) | MRK | Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms | scheduled | "NCT06136650 (A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06136650)) |
| May 2028 | [Luspatercept primary completion](https://sec-api.dev/pdufa/luspatercept) | BMY |  | scheduled | "NCT04064060 (A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-12 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04064060)) |
| May 2028 | [Nogapendekin alfa inbakicept (nai) primary completion](https://sec-api.dev/pdufa/nogapendekin-alfa-inbakicept-nai) | IBRX | Sepsis | scheduled | "NCT07783789 (NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With Sepsis): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-05-12 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07783789)) |
| May 2028 | [Tacabrutideg primary completion](https://sec-api.dev/pdufa/tacabrutideg) | ONC | CLL; Chronic Lymphocytic Leukemia; SLL | scheduled | "NCT06846671 (A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-15 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06846671)) |
| May 2028 | [TAK-881 primary completion](https://sec-api.dev/pdufa/tak-881) | TAK | Primary Immunodeficiency Diseases (PID) | scheduled | "NCT06076642 (A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-16 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06076642)) |
| May 2028 | [Vedolizumab iv primary completion](https://sec-api.dev/pdufa/vedolizumab-iv) | TAK | Ulcerative Colitis; Crohn's Disease | scheduled | "NCT06100289 (A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-16 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06100289)) |
| May 2028 | [Zola-cel primary completion](https://sec-api.dev/pdufa/zola-cel) | BMY | Lupus Erythematosus, Systemic; Lupus Nephritis | scheduled | "NCT07015983 (A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-05-17 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07015983)) |
| May 2028 | [Pelabresib primary completion](https://sec-api.dev/pdufa/pelabresib) | NVS |  | scheduled | "NCT07357727 (A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07357727)) |
| May 2028 | [Mibavademab primary completion](https://sec-api.dev/pdufa/mibavademab) | REGN | Generalized Lipodystrophy | scheduled | "NCT07220785 (Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-19 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220785)) |
| May 2028 | [Elecoglipron primary completion](https://sec-api.dev/pdufa/elecoglipron) | AZN | Type 2 Diabetes Mellitus | scheduled | "NCT07662213 (A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07662213)) |
| May 2028 | [Elecoglipron primary completion](https://sec-api.dev/pdufa/elecoglipron) | AZN | Type 2 Diabetes Mellitus | scheduled | "NCT07664553 (A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07664553)) |
| May 2028 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Chronic Spontaneous Urticaria | scheduled | "NCT07816328 (Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-24 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07816328)) |
| May 2028 | [Apg-2575(lisaftoclax ) primary completion](https://sec-api.dev/pdufa/apg-2575-lisaftoclax) | AAPG | Acute Myeloid Leukemia | scheduled | "NCT06389292 (A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-25 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06389292)) |
| May 2028 | [Ordspono™ (odronextamab) primary completion](https://sec-api.dev/pdufa/odronextamab) | REGN | B-Cell Non-Hodgkin Lymphoma (B-NHL) | scheduled | "NCT06230224 (A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06230224)) |
| May 2028 | [ORPATHYS® (savolitinib) primary completion](https://sec-api.dev/pdufa/savolitinib) | HCM | Non-small Cell Lung Cancer | scheduled | "NCT05009836 (Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-30 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05009836)) |
| May 2028 | [Velzatinib - subject to usan approval primary completion](https://sec-api.dev/pdufa/velzatinib-subject-to-usan-approval) | GSK | Gastrointestinal Neoplasms | scheduled | "NCT07218926 (A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07218926)) |
| May 2028 | [Piqray (alpelisib) primary completion](https://sec-api.dev/pdufa/alpelisib) | NVS | Lymphatic Malformations | scheduled | "NCT05948943 (Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05948943)) |
| May 2028 | [TEZSPIRE® (tezepelumab) primary completion](https://sec-api.dev/pdufa/tezepelumab) | AZN | Asthma | scheduled | "NCT06023589 (A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06023589)) |
| May 2028 | [Surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine primary completion](https://sec-api.dev/pdufa/surufatinib-combined-with-camrelizumab-nab-paclitaxel-and-gemcitabine) | HCM | Metastatic Pancreatic Cancer | scheduled | "NCT06361888 (A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06361888)) |
| May 2028 | [NIKTIMVO (axatilimab) primary completion](https://sec-api.dev/pdufa/axatilimab) | INCY | Chronic Graft-versus-host-disease | scheduled | "NCT06821542 (A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06821542)) |
| May 2028 | [Wayrilz (rilzabrutinib) primary completion](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Autoimmune Haemolytic Anaemia | scheduled | "NCT07086976 (A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07086976)) |
| May 2028 | [Drug: ivonescimab injection primary completion](https://sec-api.dev/pdufa/drug-ivonescimab) | SMMT | Metastatic Colorectal Cancer (CRC) | scheduled | "NCT07228832 (Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Summit Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07228832)) |
| May 2028 | [Vormatrogine primary completion](https://sec-api.dev/pdufa/vormatrogine) | PRAX | Epilepsy, Tonic-Clonic; Focal Seizure; Primary Generalized Seizure | scheduled | "NCT07287163 (Clinical Trial of Vormatrigine in Adult Patients With Epilepsy): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Praxis Precision Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07287163)) |

Other months: https://sec-api.dev/fda-calendar/2028-04 , https://sec-api.dev/fda-calendar/2028-06. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates May 2028: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2028-05

```bibtex
@misc{secapidev_fda_calendar_2028_05_20261116,
  title        = {PDUFA dates May 2028: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2028-05}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2028_05_20261116","title":"PDUFA dates May 2028: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2028-05","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
